Global Plasma Fractionation Market Overview 2023-2028
Plasma fractionation is a crucial process in the pharmaceutical and medical industries that involves separating various components of blood plasma into distinct fractions. It plays a critical role in producing a wide range of life-saving and life-enhancing therapies for patients with different medical conditions, including immune deficiencies, bleeding disorders, and neurological diseases. It relies on voluntary plasma donations from healthy individuals, which provides the raw material needed for the production of life-saving medications.
The global plasma fractionation market size reached US$ 23.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 33.7 Billion by 2028, exhibiting a growth rate (CAGR) of 5.8% during 2023-2028.
Global Plasma Fractionation Market Trends and Drivers:
The increasing use of plasma fractionation for producing life-saving medications, including immunoglobulins, clotting factors, and albumin, for treating various medical conditions represents one of the primary factors strengthening the market around the world. In addition, the surging incidence of chronic diseases, such as immune disorders, haemophilia, and liver diseases, that requires a steady supply of plasma-derived medications, is favoring the growth of the market. Furthermore, the increasing elderly population that is more susceptible to developing rare conditions requiring the usage of blood derivatives is propelling the growth of the market. Moreover, the rising focus on plasma-derived products like convalescent plasma for potential therapeutic benefits is contributing to the market growth. Apart from this, the growing awareness and campaigns for blood plasma donation are influencing the market positively.
Global Plasma Fractionation Market 2023-2028 Analysis and Segmentation:
Top Key Players covered in this report are: ADMA Biologics, Bio Products Laboratory Ltd., Boccard, Grifols, S.A., Hemarus Therapeutics Limited, Intas Pharmaceuticals Limited, LFB S.A., Merck Group, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., SK Plasma Co. Ltd. and Virchow Biotech Private Limited
The report segmented the market on the basis of region, product, sector, application and end user.
Breakup by Product:
- Immunoglobulins
- Albumin
- Coagulation factor VIII
- Coagulation factor IX
Breakup by Sector:
- Private Sector
- Public Sector
Breakup by Application:
- Neurology
- Immunology
- Hematology
- Other Applications
Breakup by End User:
- Hospitals and Clinics
- Clinical Research Laboratories
- Academic Institutes
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Key highlights of the report:
- Market Performance (2017-2022)
- Market Outlook (2023- 2028)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Services Private Limited.
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
